Smith & Nephew SNATS (NYSE:SNN) Price Target Raised to $35.00 at Canaccord Genuity Group

Smith & Nephew SNATS (NYSE:SNN) had its price target lifted by stock analysts at Canaccord Genuity Group from $34.00 to $35.00 in a report issued on Thursday,Benzinga reports. The brokerage presently has a “hold” rating on the medical equipment provider’s stock. Canaccord Genuity Group’s target price points to a potential upside of 0.40% from the company’s previous close.

Other equities analysts have also recently issued reports about the stock. Kepler Capital Markets raised shares of Smith & Nephew SNATS to a “strong-buy” rating in a research note on Monday, November 17th. Royal Bank Of Canada downgraded shares of Smith & Nephew SNATS from an “outperform” rating to a “sector perform” rating in a research note on Monday, December 15th. Weiss Ratings restated a “hold (c+)” rating on shares of Smith & Nephew SNATS in a research report on Wednesday, January 21st. Finally, Wall Street Zen downgraded Smith & Nephew SNATS from a “strong-buy” rating to a “buy” rating in a report on Saturday, February 21st. One research analyst has rated the stock with a Strong Buy rating and five have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $36.25.

Smith & Nephew SNATS Price Performance

NYSE SNN traded down $1.50 on Thursday, hitting $34.86. 1,823,273 shares of the stock were exchanged, compared to its average volume of 966,084. The company has a quick ratio of 1.40, a current ratio of 2.57 and a debt-to-equity ratio of 0.60. The stock has a fifty day moving average price of $34.36 and a two-hundred day moving average price of $34.95. Smith & Nephew SNATS has a 52-week low of $23.91 and a 52-week high of $38.79.

Institutional Investors Weigh In On Smith & Nephew SNATS

A number of institutional investors and hedge funds have recently bought and sold shares of SNN. Garner Asset Management Corp bought a new position in shares of Smith & Nephew SNATS during the 4th quarter worth $27,000. Arax Advisory Partners raised its holdings in shares of Smith & Nephew SNATS by 142.6% in the fourth quarter. Arax Advisory Partners now owns 968 shares of the medical equipment provider’s stock valued at $32,000 after acquiring an additional 569 shares in the last quarter. Advisors Asset Management Inc. purchased a new stake in Smith & Nephew SNATS in the fourth quarter worth about $36,000. Caitong International Asset Management Co. Ltd bought a new position in Smith & Nephew SNATS during the 3rd quarter worth about $41,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC bought a new position in Smith & Nephew SNATS during the 4th quarter worth about $43,000. 25.64% of the stock is owned by institutional investors.

Smith & Nephew SNATS Company Profile

Smith & Nephew plc is a global medical technology company specializing in the design, development and manufacture of advanced surgical devices, orthopaedic reconstruction implants, trauma and extremities products, sports medicine solutions and wound care therapies. Founded in 1856 in Hull, United Kingdom, the company has grown through both organic innovation and strategic acquisitions to offer a broad portfolio that addresses patient needs across joint replacement, minimally invasive surgery and wound healing.

In its orthopaedics business, Smith & Nephew provides hip and knee replacement systems, modular joint revision implants and biologic solutions for bone repair.